

C U R R I C U L U M V I T A E

Martin Puhr PhD

03.03.1977

Department of Urology; Medical University of Innsbruck

Anichstrasse 35

A-6020 Innsbruck

Tel.: (0043) 512-504-24826

FAX: (0043) 512-504-24817

E-mail: martin.puhr@i-med.ac.at

Nationality: Austria

Education & Employment

- 2010-present **Medical University of Innsbruck**
Postdoctoral Research Associate, Department of Urology
- 2005-2010 **Medical University of Innsbruck**
PhD student, Research Assistant, Molecular Cell Biology and Oncology (MCBO), Department of Urology, PhD awarded in January, 2010
- 2004-2005 **Military Service**
Military Hospital, Gratkorn, Austria
- 1995-2003 **Karl Franzens University & JSW/CNS Research Laboratories**
Diploma Student, Research Assistant, Diploma awarded in April, 2003

Research

- 2013-present **Group leader, Postdoctoral Research Associate**
Department of Urology, Medical University of Innsbruck (MUI), Innsbruck, Austria
- 2010-2013 **Postdoctoral Research Associate**
Department of Urology, Medical University of Innsbruck (MUI), Innsbruck, Austria
- 2008 **Research Exchange Program**
Kimmel Cancer Center, Thomas Jefferson University (TJU), Philadelphia, USA (April-September 2008)
- 2005-2010 **PhD Student Position**
Department of Urology, Medical University of Innsbruck (MUI), Innsbruck, Austria
- 2001-2003 **Research Assistant**
JSW/CNS Research Laboratories, Graz, Austria
- 2001-2003 **Diploma Student**
Diploma Thesis at the Department of Zoology, Karl F. University (KFU) and at JSW/CNS Research Laboratories, Graz, Austria

Main Areas of Research

- 2005-present Endocrine related malignancies, special focus in prostate cancer, negative feedback regulators of cytokine signaling, chemotherapy resistance mechanisms, altered miRNA expression during tumor development and progression.

Honors & Awards

2014	ESUR – Travel Award – awarded for 22 th Meeting of the EAU Section of Urological Research, Glasgow; Scotland
2014	EAU – Best Paper Award – awarded by the European Association of Urology for the best paper published in 2013 in the field of urology (first-and corresponding author), Stockholm; Sweden
2013	Sanofi-Aventis price awarded by the Medical University of Innsbruck (joint senior and corresponding author), Innsbruck; Austria
2013	ESUR/DGU – Travel Award – awarded for 21 th Meeting of the EAU Section of Urological Research, Dresden; Germany
2012	ESUR – Travel Award – awarded for 20 th Meeting of the EAU Section of Urological Research, Strasbourg; France
2012	Science – Innovation Price – awarded by the DGU, German Society of Urology (joint senior and corresponding author), Leipzig; Germany
2011	Dr. Otto Seibert Price – awarded by the Medical University of Innsbruck, Innsbruck; Austria
2010	Thesis – Award – awarded by the Austrian Cancer Foundation Tyrol, Innsbruck; Austria
2010	ESUR – Travel Award – awarded for 19 th Meeting of the EAU Section of Urological Research, Vilnius; Lithuania
2008	Alken – Price – awarded by the Alken Society for the best paper in the field of Urology (coauthor), Heidelberg; Germany
2008	ARTP – Price – awarded for the best research in the field of Urology, Barcelona; Spain
2007	SBUR – Travel Award – awarded for 7 th World Basic Urological Research Congress, Dublin; Ireland
2007	EAU – Best Paper Award – awarded by the European Association of Urology for the best paper published in 2007 in the field of urology (coauthor), Berlin; Germany

Grants & Fundraising

2015-2018	FWF Herta-Firnberg grant, 223.500 Euro (Co-applicant and mentor)
2014-2016	MUI-Start-Up grant for young scientists, 25.000 Euro
2014-2016	Cancer Foundation Tyrol, 5.000 Euro
2013-2015	Cancer Foundation Tyrol, 5.000 Euro
2013-2016	FWF grant, 337.233 Euro
2011-2013	MUI-Start-Up grant for young scientists, 77.230 Euro
2011-2013	Cancer Foundation Tyrol, 35.000 Euro

Invited speaker

2013	21th meeting of the EAU Section of Urological Research, Dresden; Germany
2013	46th Alpenländischen Urologensymposiums, Arlberg; Austria
2011	Annual meeting of the Tyrolian Cancer Foundation, Innsbruck; Austria
2009	18th meeting of the ARTP association for prostate cancer research, Paris; France
2009	The 5th Symposium & Workshop on Molecular Pathology and Histo(cyto)chemistry, organized by the Czech Society of Pathologists CLS JEP, Olomouc; Czech republic

Invited Chair

2016	31th Annual EAU Congress, Munich; Germany
2015	30th Annual EAU Congress, Madrid; Spain
2014	29th Annual EAU Congress, Stockholm; Sweden

Publication List/Last 5 Years

Original Articles:

1. Kroon J, **Puhr M**, Buijs J, van der Horst G, Hemmer DM, Marijt KA, Hwang MS, Masood M, Grimm S, Storm G, Metselaar JM, Meijer OC, Culig Z, van der Pluijm G. Glucocorticoid receptor antagonism reverts docetaxel-resistance in human prostate cancer. *Endocr Relat Cancer*. 2015 Oct 19. **IF: 4.8**
2. **Puhr M**, Hoefler J, Eigentler A, Dietrich D, van Leenders G, Uhl B, Hoogland M, Handle F, Schlick B, Neuwirt H, Sailer V, Kristiansen G, Klocker H, Culig Z. "PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer." *Oncogene*. 2015 Aug 10. **IF: 8.5**
3. Pasqualini L, Bu H, **Puhr M**, Narisu N, Rainer J, Schlick B, Schäfer G, Angelova M, Trajanoski Z, Börno ST, Schweiger MR, Fuchsberger C, Klocker H. "miR-22 and miR-29a are members of the androgen receptor cistrome modulating LAMC1 and Mcl-1 in prostate cancer." *Mol Endocrinol*. 2015 Jun 8. **IF:4.0**
4. Meidhof S, Brabletz S, Lehmann W, Preca BT, Mock K, Ruh M, Schüler J, Berthold M, Weber A, Burk U, Lübbert M, **Puhr M**, Culig Z, Wellner U, Keck T, Bronsert P, Küsters S, Hopt UT, Stemmler MP, Brabletz T. „ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat.“ *EMBO Mol Med*. 2015 Apr 14. **IF: 8.7**
5. Neuwirt H, Wabnig E, Feistritzer C, Eder IE, Salvador C, **Puhr M**, Culig Z, Massoner P, Tiefenthaler M, Steurer M, Konwalinka G. "Akacid medical formulation induces apoptosis in myeloid and lymphatic leukemic cell lines *in vitro* and *in vivo*." *PLoS One*. 2015 Feb 13. **IF: 3.5**
6. **Puhr M**, Hoefler J, Neuwirt H, Eder IE, Kern J, Schäfer G, Geley S, Heidegger I, Klocker H, Culig Z., "PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells" *Oncotarget*, 2014 Nov 17. **IF: 6.4**
7. Massoner P, Thomm T, Mack B, Untergasser G, Martowicz A, Bobowski K, Klocker H, Gires O, **Puhr M**, "EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205." *Br J Cancer*. 2014 Aug 26. (joint senior author) **IF: 4.8**
8. Hoefler J, Kern J, Ofer P, Eder IE, Schäfer G, Dietrich D, Kristiansen G, Geley S, Rainer J, Gunsilius E, Klocker H, Culig Z, **Puhr M**. "SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer." *Endocr Relat Cancer*. 2014 Jan 30;21(2):175-87. doi: 10.1530/ERC-13-0446. Print 2014 Apr. **IF: 4.8**
9. Eder IE, Egger M, Neuwirt H, Seifarth C, Maddalo D, Desiniotis A, Schäfer G, **Puhr M**, Bektic J, Cato AC, Klocker H, "Enhanced inhibition of prostate tumor growth by dual targeting the androgen receptor and the regulatory subunit type α of protein kinase a *in vivo*." *Int J Mol Sci*. 2013 Jun 4. **IF: 2.9**
10. Neuwirt H, Eder IE, **Puhr M**, Rudnicki M. "SOCS-3 is downregulated in progressive CKD patients and regulates proliferation in human renal proximal tubule cells in a STAT1/3 independent manner." *Lab Invest*. 2013 Jan. **IF: 3.7**

11. **Puhr M**, Hoefler J, Schäfer G, Erb HH, Oh SJ, Klocker H, Heidegger I, Neuwirt H, Culig Z. “Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205.” *Am J Pathol*. 2012 Oct 3. **IF: 4.6**
12. Hoefler J, Schäfer G, Klocker H, Erb HH, Mills IG, Hengst L, **Puhr M**, Culig Z, “PIAS1 Is Increased in Human Prostate Cancer and Enhances Proliferation through Inhibition of p21.” *Am J Pathol*. 2012 Mar 23. (joint corresponding and senior author) **IF: 4.6**
13. **Puhr M**, Santer FR, Neuwirt H, Marcias G, Hobisch A, Culig Z. “SOCS-3 antagonises the proliferative and migratory effects of FGF-2 in prostate cancer by inhibition of p44/p42 MAPK signalling“, *Endocr Relat Cancer*. 2010 May 18. **IF: 4.8**
14. Gu L, Vogiatzi P, **Puhr M**, Dagvadorj A, Lutz J, Ryder A, Addya S, Fortina P, Cooper C, Leiby B, Dasgupta A, Hyslop T, Bubendorf L, Alanen K, Mirtti T, Nevalainen MT. “STAT5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo“, *Endocr Relat Cancer*. 2010 May 18. **IF: 4.8**

Reviews:

1. Sampson N, Neuwirt H, **Puhr M**, Klocker H, Eder IE, „*In vitro* model systems to study androgen receptor signaling in prostate cancer” *Endocr Relat Cancer*. 2013 Mar 26. **IF: 4.8**
2. Culig Z, **Puhr M**, Interleukin-6: A multifunctional targetable cytokine in human prostate cancer. *Mol Cell Endocrinol*. 2011 Jun 1. **IF: 4.4**

Publication List/10 most important publications

Original Articles:

- 1 Kroon J, **Puhr M**, Buijs J, van der Horst G, Hemmer DM, Marijt KA, Hwang MS, Masood M, Grimm S, Storm G, Metselaar JM, Meijer OC, Culig Z, van der Pluijm G. Glucocorticoid receptor antagonism reverts docetaxel-resistance in human prostate cancer. *Endocr Relat Cancer*. 2015 Oct 19. **IF: 4.8**
- 2 **Puhr M**, Hoefler J, Eigentler A, Dietrich D, van Leenders G, Uhl B, Hoogland M, Handle F, Schlick B, Neuwirt H, Sailer V, Kristiansen G, Klocker H, Culig Z. "PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer." *Oncogene*. 2015 Aug 10. **IF: 8.5**
- 3 Meidhof S, Brabletz S, Lehmann W, Preca BT, Mock K, Ruh M, Schüler J, Berthold M, Weber A, Burk U, Lübbert M, **Puhr M**, Culig Z, Wellner U, Keck T, Bronsert P, Küsters S, Hopt UT, Stemmler MP, Brabletz T. „ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat.“ *EMBO Mol Med*. 2015 Apr 14. **IF: 8.7**
- 4 **Puhr M**, Hoefler J, Neuwirt H, Eder IE, Kern J, Schäfer G, Geley S, Heidegger I, Klocker H, Culig Z., "PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells" *Oncotarget*, 2014 Nov 17. **IF: 6.4**
- 5 Hoefler J, Kern J, Ofer P, Eder IE, Schäfer G, Dietrich D, Kristiansen G, Geley S, Rainer J, Gunsilius E, Klocker H, Culig Z, **Puhr M**. "SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer." *Endocr Relat Cancer*. 2014 Jan 30;21(2):175-87. doi: 10.1530/ERC-13-0446. Print 2014 Apr. **IF: 4.8**
- 6 **Puhr M**, Hoefler J, Schäfer G, Erb HH, Oh SJ, Klocker H, Heidegger I, Neuwirt H, Culig Z. "Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205." *Am J Pathol*. 2012 Oct 3. **IF: 4.6**
- 7 Hoefler J, Schäfer G, Klocker H, Erb HH, Mills IG, Hengst L, **Puhr M**, Culig Z, "PIAS1 Is Increased in Human Prostate Cancer and Enhances Proliferation through Inhibition of p21." *Am J Pathol*. 2012 Mar 23. (joint corresponding and senior author) **IF: 4.6**
- 8 **Puhr M**, Santer FR, Neuwirt H, Marcias G, Hobisch A, Culig Z. "SOCS-3 antagonises the proliferative and migratory effects of FGF-2 in prostate cancer by inhibition of p44/p42 MAPK signalling", *Endocr Relat Cancer*. 2010 May 18. **IF: 4.8**
- 9 Gu L, Vogiatzi P, **Puhr M**, Dagvadorj A, Lutz J, Ryder A, Addya S, Fortina P, Cooper C, Leiby B, Dasgupta A, Hyslop T, Bubendorf L, Alanen K, Mirtti T, Nevalainen MT. "STAT5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo", *Endocr Relat Cancer*. 2010 May 18. **IF: 4.8**
- 10 **Puhr M**, Santer FR, Neuwirt H, Susani M, Nemeth JA, Hobisch A, Kenner L, Culig Z. "Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways", *Cancer Res*. 2009 Sep 15. **IF: 9.3**